 UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 28, 2021 GLOBE NEWSWIRE -- Merus N.V. Nasdaq: MRUS Merus, the Company, we, or our, a clinical-stage oncology company developing innovative, full-length multispecific antibodies Biclonics and Triclonics, today announced the companys selection for oral presentation at the American Society of Clinical Oncology ASCO Annual Meeting, being held virtually June 4-8, 2021. 